Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry

Tools
- Tools
+ Tools

Huish, S. A., Fletcher, S., Dunn, Janet A., Hewison, M. and Bland, R. (2015) Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry. Journal of Steroid Biochemistry and Molecular Biology, 164 . pp. 214-217. doi:10.1016/j.jsbmb.2016.02.009

Research output not available from this repository, contact author.
Official URL: https://doi.org/10.1016/j.jsbmb.2016.02.009

Request Changes to record.

Abstract

Low serum 25(OH)D and associated bone and non-bone related problems are not well appreciated in end stage renal disease (ESRD). Vitamin D treatment strategies in the UK currently focus almost exclusively on calcitriol [1,25(OH)2D], alfacalcidol or paricalcitol. In ESRD hypovitaminosis D is associated with bone loss, muscle weakness, falls, fractures and increased inflammation. National guidelines changed in 2014 and now recommend the diagnosis and treatment of low serum 25(OH)D in all patients with glomerular filtration rate (GFR) less than 30 ml/min/1.73m2. However as yet there are no standardized guidelines for dosage, frequency and monitoring in ESRD patients. Following a systematic review of the literature we developed a clinical guideline for cholecalciferol supplementation at University Hospitals of Coventry and Warwickshire, UK. The guideline recommends 40,000IU cholecalciferol weekly for patients with 25(OH)D <50 nmol/L and 20,000IU weekly for patients with 25(OH)D 50–75nmol/L; to be continued long term unless levels increase to ≥150 nmol/L. To date we have measured 25(OH)D levels in 385 in-center haemodialysis patients. Virtually all patients (95%) had serum 25(OH)D levels <75 nmol/L (65% deficient, <30 nmol/L; 30% insufficient, 30–74 nmol/L). Only 5% of patients had optimal levels (≥75 nmol/L). Our data indicates that hypovitaminosis D is prevalent in the haemodialysis population in Coventry and Warwickshire and this is likely to reflect UK haemodialysis patients, highlighting the need for a national supplementation guideline.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit
Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Journal of Steroid Biochemistry and Molecular Biology
Publisher: Elsevier Ltd
ISSN: 0960-0760
Official Date: 1 November 2015
Dates:
DateEvent
1 November 2015Published
9 February 2016Accepted
Volume: 164
Page Range: pp. 214-217
DOI: 10.1016/j.jsbmb.2016.02.009
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us